Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V0096 CR in Solar Urticaria
NCT00483496Phase 2Completed
- Sponsor
- Orphagen Therapeutics
- Start
- Sep 2007
- Primary completion
- Apr 2008
- Modality
- Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of titanium dioxide, bisoctrizole in solar urticaria (SU), sponsored by Orphagen Therapeutics. Started Sep 2007; status: completed.
02
Drugs
titanium dioxidebisoctrizole
03
Conditions
solar urticaria (SU)
Beyond the preview
Go deeper on NCT00483496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00483496.